Skip to content

Study · Systematic review · 2025

10 results

Once-Weekly Semaglutide Versus Once-Daily Liraglutide for Weight Loss in Adults: A Meta-Analysis of Randomized Controlled Trials.

Hashmi TM, Ahmed M, Haider A, Naseem S, Jafar U, Hussain M, Iqbal J, Ali W, Ahmed R

Clinical and translational science1 Feb 2025Cited by 9 (Europe PMC)

PMID39930946 (opens in a new tab)PMCIDPMC11811509 (opens in a new tab)DOI10.1111/cts.70127 (opens in a new tab)PepBankPUB-39930946
Read at sourcePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In reviewed adults, once-weekly semaglutide reduced body weight more than once-daily liraglutide.

    In plain wordsIn reviewed adults, once-weekly semaglutide lowered body weight more than daily liraglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight
    Study

    n: not reported in source

    Comparator
    Once-daily liraglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    WMD
    −4.55
    semaglutide versus liraglutide; 95% CI -6.43 to -2.67; P < 0.01

    Source sentences

    Summary
    The results indicated that OW semaglutide significantly reduced body weight (WMD: -4.55; 95% CI: -6.43, -2.67, p < 0.01), HbA1c (WMD: -0.46; 95% CI: -0.84, -0.08; p = 0.02), and fasting plasma glucose levels (WMD: -1.23; 95% CI: -1.51, -0.95; p < 0.01) in comparison to OD liraglutide.
    3 context sentences
    Summary · context
    We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) identified through a comprehensive search of the Cochrane Library, PubMed, and ScienceDirect databases from inception until July 2024.
    Summary · context
    Statistical analysis was conducted using R version 4.4.1 with the "meta" package, employing a random effects model. Three RCTs with a total of 922 patients were included in our meta-analysis.
    Title · context
    Once-Weekly Semaglutide Versus Once-Daily Liraglutide for Weight Loss in Adults: A Meta-Analysis of Randomized Controlled Trials.
  2. 02HumanSystematic reviewEfficacy outcome

    In reviewed adults, once-weekly semaglutide reduced HbA1c more than once-daily liraglutide.

    In plain wordsIn reviewed adults, once-weekly semaglutide lowered HbA1c more than daily liraglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c
    Study

    n: not reported in source

    Comparator
    Once-daily liraglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    WMD
    −0.46
    semaglutide versus liraglutide; 95% CI -0.84 to -0.08; P = 0.02

    Source sentences

    Summary
    The results indicated that OW semaglutide significantly reduced body weight (WMD: -4.55; 95% CI: -6.43, -2.67, p < 0.01), HbA1c (WMD: -0.46; 95% CI: -0.84, -0.08; p = 0.02), and fasting plasma glucose levels (WMD: -1.23; 95% CI: -1.51, -0.95; p < 0.01) in comparison to OD liraglutide.
    3 context sentences
    Summary · context
    We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) identified through a comprehensive search of the Cochrane Library, PubMed, and ScienceDirect databases from inception until July 2024.
    Summary · context
    Statistical analysis was conducted using R version 4.4.1 with the "meta" package, employing a random effects model. Three RCTs with a total of 922 patients were included in our meta-analysis.
    Title · context
    Once-Weekly Semaglutide Versus Once-Daily Liraglutide for Weight Loss in Adults: A Meta-Analysis of Randomized Controlled Trials.
  3. 03HumanSystematic reviewEfficacy outcome

    In reviewed adults, once-weekly semaglutide reduced fasting plasma glucose more than once-daily liraglutide.

    In plain wordsIn reviewed adults, once-weekly semaglutide lowered fasting glucose more than daily liraglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseFasting plasma glucose
    Study

    n: not reported in source

    Comparator
    Once-daily liraglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    WMD
    −1.23
    semaglutide versus liraglutide; 95% CI -1.51 to -0.95; P < 0.01

    Source sentences

    Summary
    The results indicated that OW semaglutide significantly reduced body weight (WMD: -4.55; 95% CI: -6.43, -2.67, p < 0.01), HbA1c (WMD: -0.46; 95% CI: -0.84, -0.08; p = 0.02), and fasting plasma glucose levels (WMD: -1.23; 95% CI: -1.51, -0.95; p < 0.01) in comparison to OD liraglutide.
    3 context sentences
    Summary · context
    We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) identified through a comprehensive search of the Cochrane Library, PubMed, and ScienceDirect databases from inception until July 2024.
    Summary · context
    Statistical analysis was conducted using R version 4.4.1 with the "meta" package, employing a random effects model. Three RCTs with a total of 922 patients were included in our meta-analysis.
    Title · context
    Once-Weekly Semaglutide Versus Once-Daily Liraglutide for Weight Loss in Adults: A Meta-Analysis of Randomized Controlled Trials.
  4. 04HumanSystematic reviewEfficacy outcome

    In reviewed adults, once-daily liraglutide had less body-weight reduction than once-weekly semaglutide.

    In plain wordsIn reviewed adults, daily liraglutide lowered body weight less than weekly semaglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody-weight reduction magnitude
    Study

    n: not reported in source

    Comparator
    Once-weekly semaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    WMD
    −4.55
    semaglutide versus liraglutide; 95% CI -6.43 to -2.67; P < 0.01

    Source sentences

    Summary
    The results indicated that OW semaglutide significantly reduced body weight (WMD: -4.55; 95% CI: -6.43, -2.67, p < 0.01), HbA1c (WMD: -0.46; 95% CI: -0.84, -0.08; p = 0.02), and fasting plasma glucose levels (WMD: -1.23; 95% CI: -1.51, -0.95; p < 0.01) in comparison to OD liraglutide.
    3 context sentences
    Summary · context
    We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) identified through a comprehensive search of the Cochrane Library, PubMed, and ScienceDirect databases from inception until July 2024.
    Summary · context
    Statistical analysis was conducted using R version 4.4.1 with the "meta" package, employing a random effects model. Three RCTs with a total of 922 patients were included in our meta-analysis.
    Title · context
    Once-Weekly Semaglutide Versus Once-Daily Liraglutide for Weight Loss in Adults: A Meta-Analysis of Randomized Controlled Trials.
  5. 05HumanSystematic reviewEfficacy outcome

    In reviewed adults, once-daily liraglutide had less HbA1c reduction than once-weekly semaglutide.

    In plain wordsIn reviewed adults, daily liraglutide lowered HbA1c less than weekly semaglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c reduction magnitude
    Study

    n: not reported in source

    Comparator
    Once-weekly semaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    WMD
    −0.46
    semaglutide versus liraglutide; 95% CI -0.84 to -0.08; P = 0.02

    Source sentences

    Summary
    The results indicated that OW semaglutide significantly reduced body weight (WMD: -4.55; 95% CI: -6.43, -2.67, p < 0.01), HbA1c (WMD: -0.46; 95% CI: -0.84, -0.08; p = 0.02), and fasting plasma glucose levels (WMD: -1.23; 95% CI: -1.51, -0.95; p < 0.01) in comparison to OD liraglutide.
    3 context sentences
    Summary · context
    We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) identified through a comprehensive search of the Cochrane Library, PubMed, and ScienceDirect databases from inception until July 2024.
    Summary · context
    Statistical analysis was conducted using R version 4.4.1 with the "meta" package, employing a random effects model. Three RCTs with a total of 922 patients were included in our meta-analysis.
    Title · context
    Once-Weekly Semaglutide Versus Once-Daily Liraglutide for Weight Loss in Adults: A Meta-Analysis of Randomized Controlled Trials.
  6. 06HumanSystematic reviewEfficacy outcome

    In reviewed adults, once-daily liraglutide had less fasting plasma glucose reduction than once-weekly semaglutide.

    In plain wordsIn reviewed adults, daily liraglutide lowered fasting glucose less than weekly semaglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseFasting-plasma-glucose reduction magnitude
    Study

    n: not reported in source

    Comparator
    Once-weekly semaglutide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    WMD
    −1.23
    semaglutide versus liraglutide; 95% CI -1.51 to -0.95; P < 0.01

    Source sentences

    Summary
    The results indicated that OW semaglutide significantly reduced body weight (WMD: -4.55; 95% CI: -6.43, -2.67, p < 0.01), HbA1c (WMD: -0.46; 95% CI: -0.84, -0.08; p = 0.02), and fasting plasma glucose levels (WMD: -1.23; 95% CI: -1.51, -0.95; p < 0.01) in comparison to OD liraglutide.
    3 context sentences
    Summary · context
    We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) identified through a comprehensive search of the Cochrane Library, PubMed, and ScienceDirect databases from inception until July 2024.
    Summary · context
    Statistical analysis was conducted using R version 4.4.1 with the "meta" package, employing a random effects model. Three RCTs with a total of 922 patients were included in our meta-analysis.
    Title · context
    Once-Weekly Semaglutide Versus Once-Daily Liraglutide for Weight Loss in Adults: A Meta-Analysis of Randomized Controlled Trials.
  7. 07HumanSystematic reviewSafety outcome

    In reviewed adults, severe adverse effects did not differ significantly between weekly semaglutide and daily liraglutide (OR 1.66; 95% CI 0.53 to 5.16; P = 0.38; OR numerator orientation unstated).

    In plain wordsIn reviewed adults, severe adverse effects did not differ significantly between weekly semaglutide and daily liraglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeSevere adverse effects
    Study

    n: not reported in source

    Comparator
    Once-daily liraglutide
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Measurements

    OR
    1.66
    between groups; 95% CI 0.53 to 5.16; P = 0.38; OR numerator orientation unstated

    Source sentences

    Summary
    The risk of severe adverse effects (OR, 1.66; 95% CI, 0.53-5.16; p = 0.38) and gastrointestinal adverse effects (OR, 1.84; 95% CI, 0.82-4.14; p = 0.14) was comparable between both groups.
    3 context sentences
    Summary · context
    We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) identified through a comprehensive search of the Cochrane Library, PubMed, and ScienceDirect databases from inception until July 2024.
    Summary · context
    Statistical analysis was conducted using R version 4.4.1 with the "meta" package, employing a random effects model. Three RCTs with a total of 922 patients were included in our meta-analysis.
    Title · context
    Once-Weekly Semaglutide Versus Once-Daily Liraglutide for Weight Loss in Adults: A Meta-Analysis of Randomized Controlled Trials.
  8. 08HumanSystematic reviewSafety outcome

    In reviewed adults, severe adverse effects did not differ significantly between weekly semaglutide and daily liraglutide (OR 1.66; 95% CI 0.53 to 5.16; P = 0.38; OR numerator orientation unstated).

    In plain wordsIn reviewed adults, severe adverse effects did not differ significantly between weekly semaglutide and daily liraglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeSevere adverse effects
    Study

    n: not reported in source

    Comparator
    Once-weekly semaglutide
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Measurements

    OR
    1.66
    between groups; 95% CI 0.53 to 5.16; P = 0.38; OR numerator orientation unstated

    Source sentences

    Summary
    The risk of severe adverse effects (OR, 1.66; 95% CI, 0.53-5.16; p = 0.38) and gastrointestinal adverse effects (OR, 1.84; 95% CI, 0.82-4.14; p = 0.14) was comparable between both groups.
    3 context sentences
    Summary · context
    We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) identified through a comprehensive search of the Cochrane Library, PubMed, and ScienceDirect databases from inception until July 2024.
    Summary · context
    Statistical analysis was conducted using R version 4.4.1 with the "meta" package, employing a random effects model. Three RCTs with a total of 922 patients were included in our meta-analysis.
    Title · context
    Once-Weekly Semaglutide Versus Once-Daily Liraglutide for Weight Loss in Adults: A Meta-Analysis of Randomized Controlled Trials.
  9. 09HumanSystematic reviewSafety outcome

    In reviewed adults, gastrointestinal adverse effects did not differ significantly between weekly semaglutide and daily liraglutide (OR 1.84; 95% CI 0.82 to 4.14; P = 0.14; OR numerator orientation unstated).

    In plain wordsIn reviewed adults, gastrointestinal adverse effects did not differ significantly between weekly semaglutide and daily liraglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeGastrointestinal adverse effects
    Study

    n: not reported in source

    Comparator
    Once-daily liraglutide
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    OR
    1.84
    between groups; 95% CI 0.82 to 4.14; P = 0.14; OR numerator orientation unstated

    Source sentences

    Summary
    The risk of severe adverse effects (OR, 1.66; 95% CI, 0.53-5.16; p = 0.38) and gastrointestinal adverse effects (OR, 1.84; 95% CI, 0.82-4.14; p = 0.14) was comparable between both groups.
    3 context sentences
    Summary · context
    We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) identified through a comprehensive search of the Cochrane Library, PubMed, and ScienceDirect databases from inception until July 2024.
    Summary · context
    Statistical analysis was conducted using R version 4.4.1 with the "meta" package, employing a random effects model. Three RCTs with a total of 922 patients were included in our meta-analysis.
    Title · context
    Once-Weekly Semaglutide Versus Once-Daily Liraglutide for Weight Loss in Adults: A Meta-Analysis of Randomized Controlled Trials.
  10. 10HumanSystematic reviewSafety outcome

    In reviewed adults, gastrointestinal adverse effects did not differ significantly between weekly semaglutide and daily liraglutide (OR 1.84; 95% CI 0.82 to 4.14; P = 0.14; OR numerator orientation unstated).

    In plain wordsIn reviewed adults, gastrointestinal adverse effects did not differ significantly between weekly semaglutide and daily liraglutide.

    Peptide
    Liraglutide
    Outcome
    No significant changeGastrointestinal adverse effects
    Study

    n: not reported in source

    Comparator
    Once-weekly semaglutide
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Measurements

    OR
    1.84
    between groups; 95% CI 0.82 to 4.14; P = 0.14; OR numerator orientation unstated

    Source sentences

    Summary
    The risk of severe adverse effects (OR, 1.66; 95% CI, 0.53-5.16; p = 0.38) and gastrointestinal adverse effects (OR, 1.84; 95% CI, 0.82-4.14; p = 0.14) was comparable between both groups.
    3 context sentences
    Summary · context
    We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) identified through a comprehensive search of the Cochrane Library, PubMed, and ScienceDirect databases from inception until July 2024.
    Summary · context
    Statistical analysis was conducted using R version 4.4.1 with the "meta" package, employing a random effects model. Three RCTs with a total of 922 patients were included in our meta-analysis.
    Title · context
    Once-Weekly Semaglutide Versus Once-Daily Liraglutide for Weight Loss in Adults: A Meta-Analysis of Randomized Controlled Trials.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.